APELLIS PHARMACEUTICALS INC. - COMMON STOCK

32,96

26-декабря-24 16:45:00

15 мин. задержка

Акции

-0,37

-1,10%

Сегодняшний диапазон

32,33 - 33,23

ISIN

N/A

Источник

NASDAQ

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 дек 2024 16:05:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

27 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

12 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

05 ноя 2024 07:05:00 Источник Nasdaq GlobeNewswire
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

26 окт 2024 14:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

22 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

16 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

25 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

20 сен 2024 05:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 сен 2024 16:05:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

29 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

08 авг 2024 07:00:01 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 авг 2024 16:05:01 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

01 авг 2024 07:05:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

18 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

09 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

28 июн 2024 06:57:12 Источник Nasdaq GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

10 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

05 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.